How many insider trades does FilingIQ track for UNCY?

FilingIQ tracks 25 Form 4 insider transactions for UNCY (Unicycive Therapeutics, Inc.), covering filings from May 16, 2022 onwards. 16 of those were filed in the last 90 days.

Are UNCY insiders net buyers or net sellers?

Across the full Form 4 history for UNCY, 1 transactions (4%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does UNCY insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is UNCY in?

Unicycive Therapeutics, Inc. (UNCY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $182.44M.

UNCY insider trading

NasdaqCM Healthcare

Unicycive Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

4% / 0%

Market cap

$182.44M

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Company website: unicycive.com

UNCY insider activity at a glance

FilingIQ has scored 25 insider transactions for UNCY since May 16, 2022. The most recent filing in our index is dated May 14, 2026.

Across the full history, 1 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on UNCY insider trades is 61.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live UNCY trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,099

UNITED THERAPEUTICS Corp

APLS 274

Apellis Pharmaceuticals, Inc.

KYMR 232

Kymera Therapeutics, Inc.

GH 194

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for UNCY?: FilingIQ tracks 25 Form 4 insider transactions for UNCY (Unicycive Therapeutics, Inc.), covering filings from May 16, 2022 onwards. 16 of those were filed in the last 90 days.
Are UNCY insiders net buyers or net sellers?: Across the full Form 4 history for UNCY, 1 transactions (4%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does UNCY insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is UNCY in?: Unicycive Therapeutics, Inc. (UNCY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $182.44M.

Methodology & sources

Every UNCY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.